7 Golda Meir St./Weizmann Science Park
74036 Ness Ziona, il
+972 (8) 9313433
Sol-Gel Signs $27 M Deal for Dermatology Drug Delivery
Under the terms of the new agreement, Sol-Gel will receive $27 million, comprised of an initial non-refundable payment as well as additional license fees and development payments upon the successful completion of various milestones. The U.S. partner will fund the product's development. Sol-Gel will be entitled to receive royalties from net sales.
The new agreement follows a similar $25 million deal made with the same company.
"This repeat collaboration reinforces Sol-Gel's position as a leading player in the development of encapsulation technologies for application to topical drug products," said Dr. Alon Seri-Levy, co-founder and CEO.
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to firstname.lastname@example.org.